Advertisement
  • ACS
  • Publications
  • C&EN
  • CAS
  • Join ACS
  • Log in Log out
  • Chemical & Engineering News Chemical & Engineering News
  • LATEST
  • LATEST

  • TOPICS
    • Analytical Chemistry
    • Biological Chemistry
    • Business
    • Careers
    • Education
    • Energy
    • Environment
    • Food
    • Materials
    • People
    • Pharmaceuticals
    • Physical Chemistry
    • Policy
    • Research Integrity
    • Safety
    • Synthesis
    • ACS News
  • TOPICS

    • Analytical Chemistry
    • Biological Chemistry
    • Business
    • Careers
    • Education
    • Energy
    • Environment
    • Food
    • Materials
    • People
    • Pharmaceuticals
    • Physical Chemistry
    • Policy
    • Research Integrity
    • Safety
    • Synthesis
    • ACS News
  • MAGAZINE
    • Current Issue
    • Recent Issues
    • Archives: 100 Years of C&EN
  • MAGAZINE

    • Current Issue
    • Recent Issues
    • Archives: 100 Years of C&EN
  • FEATURES
    • 10 Start-ups to Watch
    • C&EN's Centennial
    • Talented Twelve
    • Trailblazers
    • Global Top 50 chemical firms
    • US Top 50 chemical firms
  • FEATURES

    • 10 Start-ups to Watch
    • C&EN's Centennial
    • Talented Twelve
    • Trailblazers
    • Global Top 50 chemical firms
    • US Top 50 chemical firms
  • COLLECTIONS
    • Career Ladder
    • In Memoriam
    • Movers and Shakers
    • Newscripts
    • Nobel Prize in Chemistry
    • Opinion
    • Periodic Graphics
    • Quizzes
    • Videos
    • What's That Stuff?
    • C&EN Webinars
    • C&EN White Papers & E-books
  • COLLECTIONS

    • Career Ladder
    • In Memoriam
    • Movers and Shakers
    • Newscripts
    • Nobel Prize in Chemistry
    • Opinion
    • Periodic Graphics
    • Quizzes
    • Videos
    • What's That Stuff?
    • C&EN Webinars
    • C&EN White Papers & E-books
  • PODCASTS
  • PODCASTS

  • CHEMPICS
  • CHEMPICS

  • JOBS
  • JOBS

    • Advanced Search
Chemical & Engineering News
  • Welcome,
  • Log out
Chemical & Engineering News
×
  • LATEST
  • LATEST

  • TOPICS
    • Analytical Chemistry
    • Biological Chemistry
    • Business
    • Careers
    • Education
    • Energy
    • Environment
    • Food
    • Materials
    • People
    • Pharmaceuticals
    • Physical Chemistry
    • Policy
    • Research Integrity
    • Safety
    • Synthesis
    • ACS News
  • TOPICS

    • Analytical Chemistry
    • Biological Chemistry
    • Business
    • Careers
    • Education
    • Energy
    • Environment
    • Food
    • Materials
    • People
    • Pharmaceuticals
    • Physical Chemistry
    • Policy
    • Research Integrity
    • Safety
    • Synthesis
    • ACS News
  • MAGAZINE
    • Current Issue
    • Recent Issues
    • Archives: 100 Years of C&EN
  • MAGAZINE

    • Current Issue
    • Recent Issues
    • Archives: 100 Years of C&EN
  • FEATURES
    • 10 Start-ups to Watch
    • C&EN's Centennial
    • Talented Twelve
    • Trailblazers
    • Global Top 50 chemical firms
    • US Top 50 chemical firms
  • FEATURES

    • 10 Start-ups to Watch
    • C&EN's Centennial
    • Talented Twelve
    • Trailblazers
    • Global Top 50 chemical firms
    • US Top 50 chemical firms
  • COLLECTIONS
    • Career Ladder
    • In Memoriam
    • Movers and Shakers
    • Newscripts
    • Nobel Prize in Chemistry
    • Opinion
    • Periodic Graphics
    • Quizzes
    • Videos
    • What's That Stuff?
    • C&EN Webinars
    • C&EN White Papers & E-books
  • COLLECTIONS

    • Career Ladder
    • In Memoriam
    • Movers and Shakers
    • Newscripts
    • Nobel Prize in Chemistry
    • Opinion
    • Periodic Graphics
    • Quizzes
    • Videos
    • What's That Stuff?
    • C&EN Webinars
    • C&EN White Papers & E-books
  • PODCASTS
  • PODCASTS

  • CHEMPICS
  • CHEMPICS

  • JOBS
  • JOBS

FOLLOW US

Grab your lab coat. Let's get started

Welcome!

Welcome!

Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.

It seems this is your first time logging in online. Please enter the following information to continue.

As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.

Not you? Sign in with a different account.

Not you? Sign in with a different account.

ERROR 1

ERROR 1

ERROR 2

ERROR 2

ERROR 2

ERROR 2

ERROR 2

Password and Confirm password must match.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ERROR 2

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

CREATE ACCOUNT
Need Help? Need Help?

Already have an ACS ID? Log in here

The key to knowledge is in your (nitrile-gloved) hands

Access more articles now. Choose the ACS option that’s right for you.

Already an ACS Member? Log in here  

Basic

$0 Community Associate

ACS’s Basic Package keeps you connected with C&EN and ACS.

  • Access to 6 digital C&EN articles per month on cen.acs.org
  • Weekly delivery of the C&EN Essential newsletter
JOIN NOW
Standard

$80 Regular Members & Society Affiliates

ACS’s Standard Package lets you stay up to date with C&EN, stay active in ACS, and save.

  • Access to 10 digital C&EN articles per month on cen.acs.org
  • Weekly delivery of the digital C&EN Magazine
  • Access to our Chemistry News by C&EN mobile app
Eligibility restrictions apply. Review ACS Membership Packages to see if you qualify.

JOIN NOW
Premium

$160 Regular Members & Society Affiliates
$55 Graduate Students
$25 Undergraduate Students

ACS’s Premium Package gives you full access to C&EN and everything the ACS Community has to offer.

  • Unlimited access to C&EN’s daily news coverage on cen.acs.org
  • Weekly delivery of the C&EN Magazine in print or digital format
  • Access to our Chemistry News by C&EN mobile app
  • Significant discounts on registration for most ACS-sponsored meetings
ACS offers discounts for some countries outside the United States. This discount is shown at checkout, if applicable.

JOIN NOW

Thank you!

Your account has been created successfully, and a confirmation email is on the way.

Your username is now your ACS ID.

CONTINUE READING
ENJOY UNLIMITED ACCES TO C&EN

The Next 5 Years of COVID-19

Credit: Kay Youn/C&EN/Shutterstock

  • March 10, 2025 | A version of this story appeared in Volume 103, Issue 6



  • Five years ago, the world stopped turning.
  • In late 2019, a virus emerged in Wuhan, China, and within weeks, it took hold across the earth. Soon, the novel coronavirus became known as SARS-CoV-2, and then more colloquially, the COVID-19 virus, as more and more people came down with the illness it caused.
  • On March 11, 2020, the World Health Organization (WHO) declared the outbreak a pandemic.


  • The WHO estimates that at least 3 million people died of COVID-19 in 2020.
  • That was before vaccines became widely available and before other treatments, like antivirals and monoclonal antibodies, could be taken outside an experimental setting.


  • Today, thanks largely to those interventions, COVID-19 is not the threat it once was. But chemistry still has a role to play.
  • Thousands of people continue to die each month, and the collection of postviral illnesses known as long COVID has affected an estimated 409 million people or more worldwide (Nat. Med. 2024, 10.1038/s41591-024-03173-6).


  • Some scientists are grappling with ways to prevent those outcomes.
  • They’re developing next-generation vaccines that last longer and are easier to store, antivirals that are tailored to people with weak immune systems, and broad interventions that could stop pathogens from exploding into pandemics.


  • Here C&EN looks at how the virus has transformed science and imagines what the next 5 years of COVID-19 might look like.
ADVERTISEMENT
cover2

Vaccine

Building a better COVID-19 vaccine

The next generation of COVID-19 vaccines promises to be safer and more effective

cover3

Drug Discovery

Pfizer readies its next-generation COVID-19 antiviral

A few key molecular tweaks help ibuzatrelvir overcome Paxlovid’s drawbacks

What's in the pipeline?
cover4

Pharmaceuticals

Is there a market for new COVID-19 drugs?

Waning interest in the virus has drugmakers trying for new angles

cover5

Careers

The great COVID-19 career rethink

Scientists say their work lives today wouldn’t exist if it weren’t for the pandemic

ADVERTISEMENT

Drug Development

The next 5 years of COVID-19

by C&EN staff
March 10, 2025 | A version of this story appeared in Volume 103, Issue 6
A close-up image of a COVID-19 virus.

Credit: Will Ludwig/Kay Youn/C&EN/Shutterstock

Advertisement

Most Popular in Pharmaceuticals

  • Novo Nordisk taps start-up for small-molecule weight-loss collaboration
  • MIT and Recursion partner for AI drug discovery tool
  • Bioprospectors mine microbial genomes for antibiotic gold
  • US FDA approves Moderna’s next-generation COVID-19 vaccine, with caveats
  • How will FDA changes reshape drug approval in 2025 and beyond?

 

Five years ago, the world stopped turning.

In late 2019, a virus emerged in Wuhan, China, and within weeks, it took hold across the earth: west through Europe, then across the Atlantic to Boston, where a biotech investor meeting became a superspreader event, dispersing the pathogen worldwide. Soon, the novel coronavirus became known as SARS-CoV-2, and then more colloquially, the COVID-19 virus, as more and more people came down with the illness it caused. On March 11, 2020, the World Health Organization (WHO) declared the outbreak a pandemic.

The WHO estimates that at least 3 million people died of COVID-19 in 2020. That was before vaccines became widely available and before other treatments, like antivirals and monoclonal antibodies, could be taken outside an experimental setting.

Today, thanks largely to those interventions, COVID-19 is not the threat it once was; refrigerated trucks are no longer parked up and down city streets to store bodies that can’t fit in morgues. But chemistry still has a role to play. Thousands of people continue to die each month, and the collection of postviral illnesses known as long COVID has affected an estimated 409 million people or more worldwide (Nat. Med. 2024, DOI: 10.1038/s41591-024-03173-6).

Some scientists are grappling with ways to prevent those outcomes. They’re developing next-generation vaccines that last longer and are easier to store, antivirals that are tailored to people with weak immune systems, and broad interventions that could stop pathogens from exploding into pandemics.

Chemical & Engineering News
ISSN 0009-2347
Copyright © 2025 American Chemical Society

You might also like...

Serving the chemical, life science, and laboratory worlds
Editorial: The best way to manage a pandemic
Serving the chemical, life science, and laboratory worlds
C&EN’s Year in Pharma 2022
Serving the chemical, life science, and laboratory worlds
C&EN’s Year in Pharma 2022: Viruses weren’t done with us

Sign up for C&EN's must-read weekly newsletter

Advertisement

Here C&EN looks at how the virus has transformed science and imagines what the next 5 years of COVID-19 might look like.

Share X
  • SHARE
  • Share on Facebook
  • Share on X
  • Share on Linkedin
  • Share on Reddit
  • WeChat
  • Email
  • Print
To send an e-mail to multiple recipients, separate e-mail addresses with a comma, semicolon, or both.
Title: The next 5 years of COVID-19
Author:
Enter the valid email address. Enter the comment. Enter the valid name Enter the valid email address.
Chemical & Engineering News will not share your email address with any other person or company.

Article:

This article has been sent to the following recipient:

Join the conversation

Contact the reporter

Submit a Letter to the Editor for publication

Engage with us on X

 
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.
GET MORE
GET MORE

The power is now in your (nitrile gloved) hands

Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.

Already have an ACS ID? Log in

Option 1

Create a free account
To read 6 articles each month from

Option 2

BEST VALUE

Join ACS
To get even more access to

ACS

ABOUT

  • About us
  • Advertise
  • Contact C&EN

Follow US

ACS Chemistry for life

  • Join ACS
  • Renew Membership
  • ACS Network

Sign up for C&EN's must-read weekly newsletter

Copyright © 2025 American Chemical Society. All Rights Reserved.

  • Help
  • Privacy Policy
  • Terms of Use